Back to search

Switzerland· 61263001

Simponi 50 mg, Injektionslösung in einer Fertigspritze

A golimumab product containing golimumabum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AB06

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedSimponi 50 mg, Injektionslösung in ei…ATCL04AB06REGISTER NO.61263001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Golimumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB06 (golimumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Golimumab · ATC L04AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
golimumabum
Manufacturer
Janssen-Cilag AG
Country
Switzerland (CH)
ATC code
L04AB06
ATC class
Golimumab
Defined daily dose
1.66 mg, P
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680612630012
    0.5 ml
    CHF 932.85

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

429 interactions on record for golimumab.

Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Golimumab · interactions on record

429 records

  • 287 severe
  • 135 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Golimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All golimumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Gotenfia
  • Iceland · Gobivaz, Gotenfia
  • Liechtenstein · Gobivaz, Gotenfia
  • Norway · Gobivaz, Gotenfia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d93c798e-e940-40c2-986a-c93ac38484a7
GET /v1/drugs/d93c798e-e940-40c2-986a-c93ac38484a7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "golimumabum 50 mg",
  "valid_from": "2010-12-01",
  "limitations": "[{\"description\":\"Die Behandlung mit Simponi bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\n<br>\\n<b>Rheumatoide Arthritis:</b> Zur subcutanen Behandlung der aktiven rheumatoiden Arthritis (nur in Kombination mit Methotrexat), wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Psoriasis-Arthritis:</b> Zur subcutanen Behandlung der Psoriasis-Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Morbus Bechterew/ Ankylosierende Spondylitis (AS):</b> Zur Behandlung des Morbus Bechterew/ Ankylosierende Spondylitis, wenn die vorausgegangene konventionelle Therapie unzulänglich war.<br>\\n<br>\\n<b>Moderate bis schwere Colitis ulcerosa:</b> Zur Behandlung erwachsener Patienten mit moderater bis schwerer Colitis ulcerosa, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war oder nicht vertragen wurde.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-12-01\"}]",
  "galenic_form": "Inj Lös 50 mg/0.5ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2010-12-01",
  "self_retention_pct": 10
}

See everything about golimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.